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E-mail address: towens@health.sdu.dk (T. Owens)In autoimmune diseases of the central nervous system (CNS), innate glial cell responses play a key
role in determining the outcome of leukocyte inﬁltration. Access of leukocytes is controlled via
complex interactions with glial components of the blood–brain barrier that include angiotensin II
receptors on astrocytes and immunoregulatory mediators such as Type I interferons which regulate
cellular trafﬁc. Myeloid cells at the blood–brain barrier present antigen to T cells and inﬂuence cyto-
kine effector function. Myelin-speciﬁc T cells interact with microglia and promote differentiation of
oligodendrocyte precursor cells in response to axonal injury. These innate responses offer potential
targets for immunomodulatory therapy.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Inﬂammation in the central nervous system (CNS) is a deﬁning
feature of multiple sclerosis (MS) and is thought to play a role in
neurodegenerative diseases such as Alzheimer’s Disease. The in-
nate signals that control CNS inﬂammation are of particular inter-
est. Even in autoimmune disease where the response initiates
outside the tissue or organ and the immune system may be per-
ceived as an invader, the target tissue has capacity to respond
and to participate by regulating the immune response. Glial cells,
speciﬁcally microglia and astrocytes, can induce, regulate and are
themselves regulated by inﬂammatory immune responses within
the CNS. We here review central features of innate immunity and
recent work from our labs that have identiﬁed novel pathways
by which glial response can contribute to CNS inﬂammation and
potentially inﬂuence regenerative responses in the CNS.cal Societies. Published by Elsevier
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.2. Multiple sclerosis spectrum diseases
Multiple sclerosis (MS) is an inﬂammatory demyelinating dis-
ease that predominantly affects young adult females [1]. MS has
a very high prevalence in Europe, especially in northern countries.
The etiology is believed to involve an infectious or other environ-
mental trigger in genetically susceptible individuals [1]. MS typi-
cally presents as a relapsing-remitting disease, which is
amenable to immune-targeted therapies, though varying between
individuals and treatments, then progresses to secondary progres-
sive MS, against which immune-directed therapies are ineffective
[1]. The inﬂammatory pathology of MS suggests either a T
cell + macrophage or antibody + complement attack on myelin
and underlying axons [2]. The speciﬁcity of inﬁltrating T cells in-
cludes reactivity to myelin proteins. Both CD4+ and CD8+ T cells
are implicated in MS [1,3].
Entry of T cells to the CNS involves a complex of interactions
that can loosely be described as ‘crossing the blood–brain barrier
(BBB)’. This is described in greater detail elsewhere [4]. Aspects
that are of particular relevance here include that following chemo-
kine and adhesion molecule driven transmigration of T cells across
the vascular endothelium and its associated basement membrane,
these T cells interact with macrophages and dendritic cells (DCs) in
the perivascular space, the ﬂuid contents of which being ultimately
contiguous with the subpial and subarachnoid compartments (dis-
cussed in [4]). The interaction with myeloid cells in perivascularB.V. Open access under CC BY-NC-ND license.
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antigenic peptides on DCs or macrophages. From this interim com-
partment T cells enter the CNS parenchyma via a chemokine and
matrix metalloproteinase-dependent migration across the glia lim-
itans, another basement membrane-associated structure that is
primarily composed of astrocyte end-feet [4]. Astrocytes are a
prominent source of many of the chemokines that regulate im-
mune cell entry to the CNS and for this and their participation in
the glia limitans they are recognized as key elements in controlling
the integrity of the BBB. Astrocytes thus play a vital role in regulat-
ing CNS inﬂammation. This is exempliﬁed by clinical consequences
of experimental astrocyte loss or disabling in experimental auto-
immune encephalomyelitis (EAE) [5,6].
The most widely-used animal model for MS is EAE, usually gen-
erated by immunization of mice with myelin proteins or peptides.
In most models, EAE is induced by CD4+ Th1 (interferon-gamma
(IFNc)-producing) or Th17 (IL-17 producing) T cells [3]. In C57BL/
6 mice EAE can be induced by immunization with myelin oligoden-
drocyte glycoprotein (MOG) or a p35–55 peptide. T cells of other
speciﬁcities are recruited to CNS inﬁltrates as disease progresses
[3]. Antibodies against MOG and other myelin antigens can pro-
mote demyelination in MS and EAE [2,3].
Innate contributions to CNS inﬂammation in MS and EAE are
well-recognized. In the absence of microglial response inﬂamma-
tion does not occur where as absence of reactive astrocytes exacer-
bates disease [5,7]. Interestingly the disparate effects of loss of
these two glial cell types may both reﬂect participation in events
at the BBB, a simplistic generalization being that reactive microglia
facilitate whereas reactive astrocytes regulate leukocyte entry. Of
particular interest are ﬁndings that suggest that reactive astrocytes
may selectively inﬂuence macrophage versus T cell inﬁltration [6].
However, microglia have other pro-inﬂammatory roles and are
implicated in both antigen presentation to T cells (see below)
and release of pro-inﬂammatory mediators [8]. The latter activity
can be induced by stimulation through innate receptors among
which the Toll-like receptors (TLRs) have received much attention
[9–12]. Ligands for such responses may include viruses, as are
thought to be implicated in causation of MS, pathogen-derived
products such as are contained in adjuvants in EAE, and endoge-
nous ligands that have been proposed as a consequence of tissue
damage or inﬂammation [12].
The ﬁrst approved therapy for MS were drugs based on the
cytokine IFNb, and this remains a mainstay of clinical manage-
ment, especially in relapsing-remitting MS. Efﬁcacy varies between
patients depending on factors that include generation of neutraliz-
ing antibodies and underlying cytokine status [1,3,13]. The pre-
dominant mechanism of action of IFNb as an MS therapy is
thought to be reduction of cell trafﬁc to the CNS, and there may
also be effects on regulatory cytokine production [1]. IFNb and
the multi-gene IFNa family comprise the Type I interferons (IFNI)
which are implicated in Toll-like receptor-driven innate responses,
notably to viral infection. The latter identiﬁes a plausible link to MS
etiology. The fact that IFNI are implicated in induction of inﬂam-
matory, e.g., antiviral immune responses, and are expressed in
blood and CNS of MS patients [19], poses a conundrum for how
IFNb can be effective as a therapy against MS. One suggestion
has been that whereas IFNa acts systemically to promote autoim-
munity, IFNb acts locally to suppress inﬂammation, possibly via
regulation of tumor necrosis factor (see [19]). IFNI signal through
a common IFNI receptor, IFNAR, a heterodimer of IFNAR1 and IF-
NAR2, which signals via Jak1/Tyk2 for STAT1/2 activation.
Although differential signaling outcomes have been described for
IFNa and IFNb, there is considerable overlap [19]. Mice that lack IF-
NAR or IFNb show exacerbated EAE and increased leukocyte inﬁl-
tration to the CNS [14–16], and IFNAR expression by myeloid
cells has been shown to be critical in this regulation [14].Considering mechanism, it has been shown that whether IFNb alle-
viates EAE depends on whether IFNc and Th1 T cells are present,
whereas in Th17 EAE as well as in relapsing-remitting MS with
high IL-17 serum titers, IFNb was ineffective [17]. Our own studies
suggest that IFNI signaling modulated leukocyte inﬁltration in re-
sponse to axonal lesion in which IFNc is not easily detected (see
below) [18]. Whether these or other cytokine-mediated effects
contribute to control of leukocyte trafﬁc, e.g., via regulation of
adhesion interactions, another likely component of the mechanism
of IFNb effects in MS and EAE, and how and whether the induction
of immune responses in the ﬁrst place might be modulated by IFNb
in MS rheumatoid arthritis and other autoimmune diseases are re-
viewed elsewhere [19]. As discussed below, results from our stud-
ies point to a role for IFNI-induced glial chemokines.3. Axonal lesion as a model for innate response in the CNS
Our general approach has been to use sterile axotomy as a trig-
ger for innate glial response, and then compare ﬁndings to those in
bona ﬁde autoimmune situations, and in combinations of the two.
This has allowed us to study mechanisms underlying immune-ini-
tiated glial responses in CNS demyelinating disease, by applying
autoreactive T cells as additional triggers of glial response, such
as in EAE (Fig. 1). Our research has shown a role for IFNI signaling
in regulating innate glial response, as well as identifying signaling
pathways for astrocytes that regulate immune access to the CNS.
Our ﬁndings show roles for CNS glia in regulating endogenous in-
nate cytokine and chemokine production, which in turn regulate
immune cell entry.3.1. Cellular sources of innate cytokines in the CNS
We have shown that microglia upregulate interferon response
factor-7 (IRF7) in response to sterile axotomy and in EAE [18]
(Salem, Khorooshi and Owens, unpublished). This implicates
microglia as a source of IFNI, a point of intuitive acceptance that
nonetheless remains to be rigorously demonstrated. Although IFNb
was detected by ELISA in the CNS of mice with EAE by Prinz et al.
[14], it is more commonly detected via surrogate markers such as
IRF7. This is true even in CNS virus infections, and reﬂects the bio-
logical potency of IFNI as an innate mediator [20]. The fact that
interferon response factors are implicated both in actual response
as well as feedforward induction of the cytokine itself means that
interpretation of such ﬁndings must always be nuanced. All cells of
the body are considered to have the capability to elicit an IFNI re-
sponse, e.g., in innate receptor response to viral infection. How-
ever, we do not ﬁnd that innate-responsive astrocytes express
detectable IRF7 in response to axonal lesion (see below). Myeloid
cells, especially DC, are favored candidate cell sources for the
induction of immune regulatory cytokine levels [3,21].
We have shown that mice lacking IRF7 develop more severe
EAE, with increased leukocyte inﬁltration to CNS (Salem, Khorooshi
and Owens, unpublished). This is broadly consistent with the pub-
lished work from Issazadeh, Fish, and Prinz and their colleagues
[14–16] that shows that mice which lack either IFNb or IFNAR
show exacerbated EAE and enhanced leukocyte inﬁltration to the
CNS in EAE. Our ﬁndings in the axonal lesion model generalize this
observation to a non-autoimmune injury-induced innate response
that may have regenerative consequences (see below). Thus
endogenous or innate IFNI production is not only induced by path-
ogen-mimicking adjuvant-based immunization, but also in re-
sponse to sterile injury in the CNS.
Prinz et al. used Cre-lox transgenic systems to show that mye-
loid cells were key responders to IFNI for regulation of EAE [14]. Ta-
ken together with results from adoptive transfers, which indicated
Fig. 1. Schematic to illustrate points referred to in this article. Panel A depicts lesion of the perforant pathway (pp) axons leading from entorhinal cortex (EC) to the dentate
gyrus (DG) of the hippocampal formation. Synapse loss resulting from axotomy leads to activation of microglia (blue) and astrocytes (purple) in the outer molecular layer of
the DG. Oligodendrocyte precursor cells (OPC, green) are also present in the DG. The glial response leads via chemokine production to leukocyte entry, which is depicted in
Panel B. T cells and macrophages cross the vascular endothelium in the post-capillary venules to enter perivascular space and then cross the astrocytic (Astro) glia limitans to
enter the CNS parenchyma, where they can interact with microglia (Micro). Interaction with myeloid cells also occurs within the perivascular space. Type I IFN (IFNa/b)
produced by microglia acts on astrocytes and microglia to reduce chemokine expression which contributes to Type I IFN control of leukocyte inﬁltration. Macrophage
inﬁltration is also controlled by angiotensin II (Ang II) signaling via the Ang II-receptor-1 (AT1). For simplicity, leukocyte entry during EAE (Panel C) is considered to be
similarly controlled. (Panel D) T cells that enter the CNS promote myelin clearance by co-inﬁltrating macrophages (M) and by resident microglia (Micro). Interaction of
oligodendrocyte precursor cells (OPC) with these results in differentiation to mature oligodendrocytes (Oligo).
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derived [15] and not a T cell [14], there are clear pointers that mye-
loid cells, perhaps within the CNS, participate in IFNI regulation of
inﬂammation. Our ﬁndings add that CNS microglia are a likely
source of IFNI and we would propose that this contributes to nat-
ural regulation of autoimmune CNS inﬂammation.
3.2. Regulation of non-autoimmune leukocyte inﬁltration by innate
cytokines in the CNS
Mice lacking IFNAR show 2-fold increased glial chemokine
expression and leukocyte inﬁltration to the hippocampus in re-
sponse to sterile axotomy [18]. This complements previously-de-
scribed ﬁndings in EAE [14–16]. Thus, IFNI response may
regulate immune cell entry to the CNS regardless of the primary in-
ducer or the outcome. Although this leaves unanswered the rela-
tive roles of IFNa and IFNb, it expands our understanding of the
contribution of IFNI signaling to innate CNS response. Taken to-
gether with other observations that TLR signaling controls injury-
reactive leukocyte inﬁltration to the hippocampus (reviewed in
[11]), this has general implications for autoimmune and host-pro-
tective immune responses in that some innate signals are respon-
sible for initiating response, as in the case of a viral infection, and
others may limit the extent of inﬂammation. Such coordination be-
tween immune system and the target tissue of response reﬂects
highly-evolved regulation.3.3. Antigen-presenting roles for CNS-resident myeloid cells
The ability of the tissue environment to regulate local inﬂam-
mation may extend to the quality of autoreactive T cell response.
It is well-established that transfer of experimentally-biased Th1
or Th17 CD4 T cells is an effective means of inducing EAE [3] and
that depending on the cytokine proﬁle of the transferred T cells,
their localization within the CNS and outcome of response may dif-
fer [22,23]. But there have also been reports that the CNS itself may
participate in the promotion of a Th1 response [24]. This would im-
ply activity of CNS-resident antigen-presenting cells and perivas-
cular DC are an obvious candidate, because of their location.
Microglia may also present antigen for secondary T cell response
[25] and a CD11c+ microglial subpopulation that arises during
demyelinating or inﬂammatory responses is of particular interest
[26]. However the location of CNS resident DC at extra-parenchy-
mal sites [21,27] makes a compelling argument that they would
play a key role. Demonstration that a CNS-resident cell could inﬂu-
ence Th1 or Th17 cytokine proﬁles is achieved via in vitro analysis
of cells that can be isolated relatively straightforwardly [25,26].
Such approaches rely on ﬂow cytometric phenotypes including
those based on relative CD45 levels being useful indicators of the
microenvironment from which the cell derived in vivo [25,26]. Di-
rect intervention in vivo is possible via local application of replica-
tion-defective viral vectors. We have taken this approach to
introduce adenovirus which express IL-18 binding protein to the
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[28]. This protein is a natural inhibitor of IL-18 which is implicated
in the induction of IFNc and thus a Th1 response. Unexpectedly we
ﬁnd that adenoviral IL-18 binding protein inhibits the production
of Th17-inducing cytokines when DC were infected in vitro, and
correspondingly this adenovirus inhibited IL-6, IL-23, and TGFb,
Th17 responses and EAE, when administered in vivo [28]. While
the precise molecular details of how IL-18 and its binding protein
works remain unclear [28,29], it is striking that introduction of a
viral vector encoding a regulatory protein known to affect cytokine
production by DC, to the same compartment where perivascular
and subarachnoid DC are found, could so convincingly switch a
peripherally-immunized Th17 response to (in this case) a dis-
ease-regulatory Th1 response. The implication is that T cells are
susceptible to effector modulation as they transit the perivascular
space. Whether analogous effects are mediated by other antigen-
presenting cells within the CNS parenchyma, as might conceivably
be involved in epitope spreading [3], remains to be established.4. Cytokine production by innate immune cells in the CNS
Recent studies have shown a related role for T cells that express
a gamma–delta TCR (c/d cells) in EAE, notably the ability to pro-
duce IL17 in response to the caspase-1-processed cytokines IL1b
or IL18 [30]. c/d T cells are considered an innate T cell subset, be-
cause of their limited repertoire and recognition of invariant, fre-
quently tissue-associated antigens that is independent of antigen
processing and MHC I or II association. c/d T cells are also a source
of IFNc. They are cytotoxic towards oligodendrocytes, and have
long been known to be present in the CNS of MS patients as well
as in EAE, where they have variously been reported to be pro-path-
ogenic and protective (reviewed in [10,31]). Now that a role has
been described for this cell type in EAE as an innate source of
inﬂammatory cytokines and thus that they bridge innate and adap-
tive immunity, there is even more reason to understand the precise
contribution of c/d T cells to MS, as well as other autoimmune dis-
eases. The fact that EAE is attenuated in mice that lack c/d cells (see
[10,31]) conﬁrms the importance of their role.
Another unconventional or innate T cell lineage that is impli-
cated in regulation of inﬂammatory cytokines in MS and EAE is
the natural killer (NK)-T cell, which share properties of NK cells
(see below) and T cells. NK-T cells have a limited antigen-recogni-
tion repertoire due to expression of an invariant TCRa chain, and
are particularly noted for their response to CD1d-associated lipid
epitopes. Like c/8 cells, they have been implicated both as protec-
tive and pro-pathogenic. They are a source of regulatory cytokines
and also a source of IFNc and IL17 [10].
Other innate cell types that are implicated in regulation of MS
and EAE include natural killer (NK) cells and mast cells. The role
of these cells has been recently reviewed [10]. Despite their cyto-
toxic potential, which they share with c/d and NKT cells, NK cells
are more strongly implicated in regulation of MS and EAE, and it
is thought, again like NKT and c/d T cells, that cytokine secretion
is the primary mechanism of this effect [10]. Mast cells likewise
have been suggested to have multiple roles in MS despite their
obvious potential for cytoxicity via degranulation. The fact that
all of these innate immune cell types can be shown to exert regu-
latory effects via cytokine production, in parallel with more dra-
matic cytotoxic activity in responses against pathogens, allows
speculation that they normally play a tonic or homeostatic role
in the CNS and that this is a key component of the CNS innate im-
mune response.
Nevertheless, innate cytotoxicity likely plays an important role
in pathogenesis. Microglia are implicated as a source of both
reactive nitrogen and oxygen species. These mediators are keyelements in anti-pathogen defences, especially when produced
by peripheral macrophages. Reactive oxygen species (ROS) have
been shown to mediate oligodendrocyte and neuronal cytolysis
and are thus strongly implicated as effector in demyelination and
axonal damage in MS [1,2]. Metalloproteases and myeloperoxidas-
es are also produced by activated macrophages and microglia in
the CNS and contribute to reactive tissue damage in MS and EAE
[1,2,8,10]. Phagocytosis of degraded myelin sets up a feed-forward
loop involving the adaptive immune response, as has already been
discussed. It is important to keep in mind that microglia, like in-
nate immune cells, probably normally have a homeostatic role,
i.e. they were not placed in the CNS in order to cause MS. Thus,
their potential for regulation of inﬂammation must also to consid-
ered, as will be discussed below.5. Innate immune functions of astrocytes
The ultimate barrier to entry of leukocytes to the CNS paren-
chyma is the glia limitans and this focuses attention to astrocytes.
Astrocytes that are activated in response to sterile axotomy do not
express IRF7 but do express and phosphorylate STAT1 and STAT2
(which act as signal transducers downstream of IFNAR), and are
a potent source of chemokines. NFjB-and IFNAR-signaling path-
ways have been shown to regulate the STAT2 and chemokine re-
sponses, respectively, and thus there is general convergence with
response to IFNI [18,32]. The importance of the NFjB signaling
pathway was shown in transgenic mice that express a dominant
negative IjBa which can not dissociate from NFjB, selectively in
astrocytes under control of a GFAP promoter [33]. Stereotactic
axotomy in these mice resulted in half the normal level of CCL2
message and of locally-inﬁltrating leukocytes [32]. The dichotomy
between this decreased leukocyte inﬁltration and the increase in
mice lacking IFNAR poses difﬁculties for mechanistic linkage, other
key differences being that STAT2 and CCL2 were not affected by IF-
NAR deﬁciency [32]. It is nevertheless apparent that astrocytes
contribute signiﬁcantly to innate chemokine responses and that
such responses are regulated by microglial-derived IFNI, in the sit-
uation where response is initiated within the CNS. It is tempting to
speculate that an analogous microglial-astroglial axis might oper-
ate under circumstances of immune inﬂammation in the CNS,
where post-inﬁltration microglial response might then act as a
brake on further immune cell entry via regulation of astrocytes
at the glia limitans. The extent to which such a natural regulatory
mechanism might normally act to prevent emergence of clinical
pathology is unknown.
5.1. Selective control by astrocytes of macrophage versus T cell
inﬁltration
The renin angiotensin system is well-described for its regula-
tion of vascular tone and blood pressure under conditions of acute
stress. Components of the renin-angiotensin system are also ex-
pressed in the CNS and are implicated in vascular responses, espe-
cially in stroke [34]. Given the need for vascular integrity for
normal CNS functioning and the association of blood–brain barrier
breakdown with MS, we and others have asked whether the renin-
angiotensin system and especially angiotensin II play a role. Wosik
et al. showed that human astrocytes are a source of angiotensin II
that can act via angiotensin II receptor I (AT1) on endothelial cells,
and that AT1 was upregulated in MS [35]. In contrast to human
CNS, AT1 is expressed by astrocytes in rodents, not by endothelial
cells, and we have conﬁrmed this in mice [36]. AT1 was upregu-
lated speciﬁcally by astrocytes in the dentate gyrus following axo-
nal injury. We further showed that AT1 blockade by in vivo
administration of the speciﬁc inhibitor candesartan led to
3810 B. Finsen, T. Owens / FEBS Letters 585 (2011) 3806–3812increased inﬂux of macrophages, but not T cells, in response to
axonal lesion [36]. This suggested a role for Ang II signaling to
astrocytes for maintenance of blood–brain barrier integrity.
Nevertheless, we could not detect overt blood–brain barrier break-
down in candesartan-treated mice, nor is blood–brain barrier
breakdown (as measured by horseradish peroxidase leakage to
parenchyma) a feature of this innate response model. Our ﬁndings
stand in apparent contrast to those of 2 other groups who have
shown that AT1 blockade either with candesartan or with losartan
led to amelioration of EAE and reduced T cell and macrophage inﬁl-
tration to the CNS [37,38]. One could assume that this reﬂects dif-
ferences between autoimmune versus innate astrocyte response.
We cannot otherwise explain the discrepant results regarding
AT1 and leukocyte entry but they stand as a caution to those
who would exploit this receptor system for MS therapy. We also
ﬁnd that inactivation of astrocytes by gancyclovir treatment of
GFAP/HSVtk-Tg mice exacerbated EAE, and enhanced macrophage
inﬁltration [6]. Despite that the thymidine kinase transgene is de-
signed to be a ‘suicide’ gene for cells expressing it when treated
with gancyclovir, our experience matches that of Heppner et al.
with microglia [7], in that astrocytes were not markedly depleted
in gancyclovir-treated mice in the time frame of our experiment,
nor was there a signiﬁcant loss of aquaporin-4 staining [6]. Never-
theless, there was a pronounced effect on EAE with selective in-
crease in macrophage inﬁltration. Exacerbation of EAE by such
intervention was also shown by Voskuhl et al., who emphasized
the protective aspects of the reactive astrocyte scar [5]. The fact
that gancyclovir treatment was initiated at the time of onset of
EAE in our study may have contributed to the selectivity for mac-
rophage entry, given that T cells had already inﬁltrated the CNS.
Thus by both AT1 blockade and astrocyte disabling, astrocytes at
the glia limitans are thus implicated as ‘gatekeepers’ for the brain
[36], whether under innate or autoimmune conditions, and they
selectively control macrophage versus T cell entry, at least in the
experimental systems that we have applied.6. Interface between innate and adaptive immunity
It is well-accepted that the innate response sets the stage for
the evolution of an adaptive response. In this regard it is of interest
whether the innate response induces a pro-inﬂammatory or anti-
inﬂammatory milieu, corresponding to the M1 and M2 environ-
ments that have been described for macrophage activation [39],
and if the outcome of an adaptive response superimposed on an in-
nate response is of beneﬁt to the host. The concept that inﬂamma-
tory responses are deleterious derives from pathological
circumstances that may be interpreted as over-reactions on the
part of the immune system, which would otherwise have been se-
lected through evolution for host-beneﬁt. Experimental systems
based on mild injury where repair is both desirable and possible
may have better potential to reveal beneﬁcial aspects of inﬂamma-
tory responses than models based on infection or infection-mim-
icking adjuvants, where the goal is to expel a pathogen
regardless of collateral damage, or models of cerebral catastrophes
such as stroke and hemorrhages, where the primary goal is the sur-
vival of the individual. These somewhat philosophical consider-
ations receive support from recent ﬁndings, that have shown a
beneﬁcial outcome of interaction between autoimmune T cells
and CNS microglia at the level of oligodendrogenesis following
mild injury.
6.1. T cell inﬁltration to sites of innate glial response
The interface between innate and adaptive immunity in the
brain is exempliﬁed by downstream consequences of leukocyteentry induced by sterile injury in the form of stereotactic transec-
tion (axotomy) of the entorhino-dentate perforant pathway [40]
(Fig. 1A). Recent ﬁndings suggest that inﬁltrating myelin-speciﬁc
T cells stimulate microglial-macrophage responses and cytokine
production [41]. Although T cells normally inﬁltrate the hippocam-
pal formation following perforant pathway transection, the num-
ber of T cells inﬁltrating the neural parenchyma is very limited
[41,42]. Numbers of T cells inﬁltrating the neural parenchyma,
however, increased dramatically when myelin-speciﬁc CD4+ T
cells were adoptively transferred to these mice prior to axotomy
[41]. Such inﬁltration was lesion-dependent, arguing that the axo-
nal lesion-induced astro- and microglial response induced the
microvascular endothelial cells to upregulate their expression of
adhesion molecules, critical for leukocyte trafﬁcking across the
BBB [4]. This points to a fast and efﬁcient signaling by the glial
cells, that initially sensed the degeneration of axons and terminals,
to the endothelial cells, leading to a lesion-speciﬁc immune cell
recruitment.
While cellular recruitment was at least in part due to glial ex-
pressed chemokines [43], facilitated by increased expression of
adhesion molecule expression [4], the continued presence of T cells
in the neural parenchyma depended on antigen speciﬁcity, in that
numbers of inﬁltrating T cells were approximately 100-fold higher
than in controls only when myelin-speciﬁc T cells had been trans-
ferred and not when ovalbumin-speciﬁc T cells were transferred
[41]. It can be assumed that this reﬂects interaction with cells pre-
senting myelin antigens, which would be consistent with the up-
take of myelin basic protein (MBP) in microglia-macrophages
[41], although the exact identity, location and molecular details
of the T cell-antigen presenting cell transaction remain to be eluci-
dated. Detection of message for Th1 cytokines and scattered IFNc-
producing cells, visualized by in situ hybridization, support that a
T-cell receptor-driven activation event had occurred [44].
6.2. Microglial activation by T cells
Consequences of the elevated myelin-speciﬁc Th1 cell inﬁltra-
tion observed in zones with axon and synapse degeneration
pointed towards a pro-regenerative role for activated T cells. Thus
Th1 cell inﬁltration stimulated microglial cell population expan-
sion and cytokine expression, and dramatically increased microgli-
al-macrophage phagocytosis and clearance of myelin debris, which
has been shown to be a prerequisite for successful axonal out-
growth and remyelination in other experimental systems [45].
Although the perforant pathway ﬁbers are thinly myelinated with
multiple boutons on passage [40], transected perforant pathway ﬁ-
bers are thought to undergo anterograde axonal (Wallerian)
degeneration in the same way as heavily myelinated ﬁber tracts
distal to sites of axonal transection in brain and spinal cord. Since
the hippocampal formation is part of the cerebral cortex, the per-
forant pathway deafferented dentate gyrus also shares features
with MS lesions of the cortical grey matter, that appears to be dom-
inated by activated microglia. Importantly, grey matter lesions are
already present in relapsing-remitting and acute MS and become
more prominent in secondary progressive MS [2]. If antero- and
retrograde neurodegenerative phenomena play a role in the forma-
tion of cortical lesions, studies of lesion-speciﬁc T-cell recruitment
and its consequences will be relevant to understand the pathobiol-
ogy of these lesions.
6.3. T cell-stimulated oligodendrogenesis
Remyelination of denuded axons is a component of the eventual
functional recovery which takes place over a period of days to
months [46]. It should be understood, that since the transected
perforant pathway axons do not grow back into the dentate gyrus,
B. Finsen, T. Owens / FEBS Letters 585 (2011) 3806–3812 3811the regenerative response in the dentate gyrus consists of collat-
eral sprouts from other afferent ﬁber systems, that also trigger a
myelination response [44,47]. This is consistent with other work
from us, showing that lesion-induced axonal sprouting in the regio
inferior hippocampus was associated with generation of new oligo-
dendrocytes and signiﬁcant increase in the length of myelinated ﬁ-
bers [48]. Although not known with certainty, it seems likely that
myelination of sprouting axons is regulated by some of the same
signals that regulate remyelination of denuded axons as occurs in
plaques in the CNS of patients with MS. In both circumstances
the initial step is stimulation of the ubiquitously present oligoden-
drocyte precursor cells to proliferate and differentiate into new oli-
godendrocytes [44,47]. We found that myelin-speciﬁc T cells
stimulated the generation of new oligodendrocytes via differentia-
tion of newly generated precursor cells. Whether this was due to
pro-differentiative cytokines or trophic factors acting directly on
oligodendrocyte precursor cells, or cytokines or trophic factors act-
ing indirectly on them via microglia and/or neurons remains to be
established. Note that although not addressed by our study, a role
for astrocytes as another T-cell-driven glial source of neurotro-
phins cannot be excluded. We originally speculated that the ob-
served effects were due to CD4+ Th2 cells producing IL-4 acting
on microglia to downregulate TNF and upregulate lesion-induced
production of insulin-like growth factor-1, the latter being neuro-
protective and a stimulant of oligodendrogenesis [46], or to pro-
duction of oligodendrotrophic brain derived neurotrophic factor
(BDNF) by these cells [49]. The observation of a predominant Th1
response in this model, however, calls attention to the fact that
IFNc-producing Th1 cells may, like Th2 cells, themselves produce
BDNF [49]. The likely involvement of CNS innate microglia in the
induction of these potentially protective adaptive responses rein-
forces that innate immunity in the CNS, although it can be destruc-
tive, is of beneﬁt to the host if adequately regulated.
7. Concluding remarks
We have reviewed roles for innate, mostly glial, response in the
CNS that direct and control entry of leukocytes to the CNS, that reg-
ulate immune responses within the CNS and which may translate
an immune provocation towards a CNS-regenerative or -protective
outcome. In all cases studied the ﬁndings reveal a capacity for the
CNS, often considered a ‘target tissue’ to actively participate in
interaction with the immune response.
Implications for MS include that for optimal effect of therapies
which seek to modulate immune response they should have access
to the CNS as well as act peripherally, since regulation of the im-
mune response continues after parenchymal entry. There are also
likely to be beneﬁts from exploitation of intra-CNS endogenous
immunoregulatory systems, the IFNI pathway representing an obvi-
ous example, that is currently mimicked by exogenous application
of one of its activating ligands. These perspectives have not at-
tempted to deal with heterogeneity within the MS spectrum of dis-
eases, which likely contribute to some of the perceived treatment
failures. However, it seems clear that tailoring of therapies to a bet-
ter-understood CNS-immune dialoguewill be theway of the future.
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